Friday , October 20 2017
Home / KEEP BUT DO NOT DISPLAY / Did You Know / SGLT-2 Inhibitor Gets Turned Down by the FDA

SGLT-2 Inhibitor Gets Turned Down by the FDA

Quality issues in the manufacturing plant prevents FDA from final approval. The investigational type 2 diabetes drug empagliflozin won’t win the FDA’s approval until "previously observed deficiencies" at a manufacturing plant are fixed. Eli Lilly and its partner, Boehringer Ingelheim, said the FDA had issued a complete response letter in regard to their application to market empagliflozin, a sodium glucose co-transporter-2 (SGLT-2) inhibitor. (See Item #8.)